Circulating cell free DNA as a biomarker in the serum of colorectal cancer patients

Alhanafy, Alshimaa Mahmoud; Shafei, M El; Safan, Manal A; Elnour, ElsayedS Abou; Habib, Mona Salah El‐din; Rageh, Tarek M; El-Din, Aly

doi:10.1093/annonc/mdx510

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, quantification of cfDNA by qPCR is simple, inexpensive, and reproducible ( 22 ). The concentration of cfDNA in plasma has been widely studied in patients with various neoplasms, including hepatocellular carcinoma (HCC), breast cancer, renal cell carcinoma (RCC), gastric cancer, and CRC ( 10 - 13 , 23 - 27 ). The concentration of ALU and GAPDH in CRC was found to be significantly higher than in standard control groups ( 10 - 13 ).…”

Section: Discussionmentioning

confidence: 99%

“…The concentration of cfDNA in plasma has been widely studied in patients with various neoplasms, including hepatocellular carcinoma (HCC), breast cancer, renal cell carcinoma (RCC), gastric cancer, and CRC ( 10 - 13 , 23 - 27 ). The concentration of ALU and GAPDH in CRC was found to be significantly higher than in standard control groups ( 10 - 13 ). A higher concentration of ACTB has been observed in HCC and RCC than in healthy groups ( 23 , 26 ).…”

Section: Discussionmentioning

confidence: 99%

“…The concentration of cfDNA has been identified as a potential prognostic biomarkers in CRC. The concentration of cfDNA based on different primers has been found to be significantly higher in CRC than in healthy volunteers and intestinal polyp patients ( 10 - 13 ). However, different primers in CRC have not yet been compared.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Different primers for diagnosing circulating cell-free DNA of colorectal cancer

Shi¹,

Li²,

Liao³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background Cell-free DNA (cfDNA) primers have been designed to screen for cancer diagnosis, but the results have been inconsistent. The study aimed to compare different primers for diagnosing cfDNA of colorectal cancer (CRC). Methods Peripheral blood specimens were collected from 71 patients with CRC and 20 patients with proliferative intestinal polyps. Quantitative polymerase chain reaction (q-PCR) was used to detect the concentration of cfDNA of these primers, including ALU elements (ALU), Beta-actin (ACTB), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The receiver operator characteristic curve (ROC) was performed to analyze the diagnostic value. Results The concentration of cfDNA in plasma of the CRC group determined by primers ALU and GAPDH was significantly higher than that of the intestinal polyp group (P<0.05). There was no significant difference in cfDNA level determined by primer ACTB between the CRC group and the intestinal polyp group (P>0.05). The area under curves (AUCs) of ALU, GAPDH, and ACTB were 0.734, 0.800, and 0.503, respectively. Conclusions The GAPDH and ALU in plasma are expected to be sensitive indicators for the diagnosis of CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Different primers for diagnosing circulating cell-free DNA of colorectal cancer

Shi¹,

Li²,

Liao³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

Ultrasensitive amperometric aptasensor for the epithelial cell adhesion molecule by using target-driven toehold-mediated DNA recycling amplification

Chen

Shang

et al. 2018

Microchim Acta

View full text Add to dashboard Cite

An amperometric aptasensor is reported for the electrochemical determination of the epithelial cell adhesion molecule (EpCAM). It is based on a combination of EpCAM-driven toehold-mediated DNA recycling amplification, the specific recognition of EpCAM aptamer, and its binding to EpCAM. Hairpin probe 1 (Hp1) with a toehold region was modified with a 5'-thiol group (5'-SH) and self-assembled onto the surface of a gold electrode. Upon addition of EpCAM, the probe A (a 15-mer) is liberated from the aptamer/probe A complex and then hybridizes with the toehold domain of Hp1. This results in the exposure of another toehold for further hybridizing with hairpin probe 2 (Hp2) to displace probe A in the presence of Hp2 that was labeled with the electrochemical probe Methylene Blue (MB). Subsequently, liberated probe A is hybridized again with another Hp1 to start the next round of DNA recycling amplification by reusing probe A. This leads to the formation of plenty of MB-labeled DNA strands on the electrode surface and generates an amplified current. This 1:N probe-response amplification results in ultrasensitive and specific detection of EpCAM, with a 20 pg·mL detection limit. The electrode is highly stable and regenerable. It was successfully applied to the determination of EpCAM in spiked human serum, urine and saliva, and thus provides a promising tool for early clinical diagnosis. Graphical abstract Schematic illustration of the electrochemical detection for EpCAM. The method is based on aptamer-based recognition and EpCAM-driven toehold-mediated DNA recycling amplification. Hp1: Hairpin probe 1; Hp2: Hairpin probe 2; MB: Methylene blue; MCH: 6-Mercapto-1-hexanol; EpCAM: Epithelial cell adhesion molecule.

show abstract

Circulating cell free DNA as a biomarker in the serum of colorectal cancer patients

Cited by 2 publications

References 0 publications

Different primers for diagnosing circulating cell-free DNA of colorectal cancer

Different primers for diagnosing circulating cell-free DNA of colorectal cancer

Ultrasensitive amperometric aptasensor for the epithelial cell adhesion molecule by using target-driven toehold-mediated DNA recycling amplification

Contact Info

Product

Resources

About